July 25, 2014 5:07 PM ET


Company Overview of Neurogen Corporation

Company Overview

Neurogen Corporation develops new small molecule drugs for psychiatric and neurological disorders. The company’s clinical development programs include aplindore, which is in Phase II clinical trials for the treatment of Parkinson’s disease and restless legs syndrome; and MK 2295, a VR1 receptor antagonist that is in preclinical development for the treatment of pain and cough. It has a collaboration and licensing agreement with Merck Sharp & Dohme Limited to research, develop, and commercialize small molecule medicines that work by targeting the VR1 receptor; and a licensing agreement with Wyeth Pharmaceuticals to acquire worldwide rights to aplindore. The company was founded in 1987 and is b...

45 Northeast Industrial Road

Branford, CT 06405

United States

Founded in 1987

6 Employees





Key Executives for Neurogen Corporation

Vice President of Drug Metabolism and Pharmacokinetics
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Strategic Science & Technologies, LLC United States
RayBiotech, Inc. United States
Coserics, LLC United States
LifeGen Technologies LLC United States
Samumed, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Neurogen Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.